Literature DB >> 29770915

Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.

Sumana Narayanan1, Tsutomu Kawaguchi1, Li Yan2, Xuan Peng2, Qianya Qi2, Kazuaki Takabe3,4,5,6,7,8.   

Abstract

BACKGROUND: Elevated tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment is a known positive prognostic factor in colorectal cancer (CRC). We hypothesized that since cytotoxic T cells release cytolytic proteins such as perforin (PRF1) and pro-apoptotic granzymes (GZMA) to attack cancer cells, a cytolytic activity score (CYT) would be a useful tool to assess anticancer immunity.
METHODS: Genomic expression data were obtained from 456 patients from The Cancer Genome Atlas (TCGA). CYT was defined by GZMA and PRF1 expression, and CIBERSORT was used to evaluate intratumoral immune cell composition.
RESULTS: High CYT was associated with high microsatellite instability (MSI-H), as well as high levels of activated memory CD4+T cells, gamma-delta T cells, and M1 macrophages. CYT-high CRC patients had improved overall survival (p = 0.019) and disease-free survival (p = 0.016) compared with CYT-low CRC patients, especially in TIL-positive tumors. Multivariate analysis demonstrated that CYT- high associates with improved survival independently after controlling for age, lymphovascular invasion, colonic location, microsatellite instability, and TIL positivity. The levels of immune checkpoint molecules (ICMs)-programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), lymphocyte-activation gene 3 (LAG3), T cell immunoglobulin and mucin domain 3 (TIM3), and indoleamine 2,3-dioxygenase 1 (IDO1)-correlated significantly with CYT (p < 0.0001); with improved survival in CYT-high and ICM-low patients, and poorer survival in ICM-high patients.
CONCLUSIONS: High CYT within CRC is associated with improved survival, likely due to increased immunity and cytolytic activity of T cells and M1 macrophages. High CYT is also associated with high expression of ICMs; thus, further studies to elucidate the role of CYT as a predictive biomarker of the efficacy of immune checkpoint blockade are warranted.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29770915      PMCID: PMC6237091          DOI: 10.1245/s10434-018-6506-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

Review 1.  The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Authors:  Gregory K Pennock; Laura Q M Chow
Journal:  Oncologist       Date:  2015-06-11

2.  Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).

Authors:  Sara Y Kim; Tsutomu Kawaguchi; Li Yan; Jessica Young; Qianya Qi; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

3.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

4.  Classification and characterization of microsatellite instability across 18 cancer types.

Authors:  Ronald J Hause; Colin C Pritchard; Jay Shendure; Stephen J Salipante
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

5.  Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer.

Authors:  Jonna Berntsson; Björn Nodin; Jakob Eberhard; Patrick Micke; Karin Jirström
Journal:  Int J Cancer       Date:  2016-05-06       Impact factor: 7.396

Review 6.  DNA mismatch repair gene mutations in human cancer.

Authors:  P Peltomäki
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

7.  Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.

Authors:  James H Park; Arfon G Powell; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Joanne Edwards
Journal:  Br J Cancer       Date:  2016-02-09       Impact factor: 7.640

8.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

9.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.

Authors:  Antonio Colaprico; Tiago C Silva; Catharina Olsen; Luciano Garofano; Claudia Cava; Davide Garolini; Thais S Sabedot; Tathiane M Malta; Stefano M Pagnotta; Isabella Castiglioni; Michele Ceccarelli; Gianluca Bontempi; Houtan Noushmehr
Journal:  Nucleic Acids Res       Date:  2015-12-23       Impact factor: 16.971

10.  Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival.

Authors:  Jessica Young; Tsutomu Kawaguchi; Li Yan; Qianya Qi; Song Liu; Kazuaki Takabe
Journal:  Oncotarget       Date:  2017-10-06
View more
  63 in total

1.  Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.

Authors:  Kerry-Ann McDonald; Tsutomu Kawaguchi; Qianya Qi; Xuan Peng; Mariko Asaoka; Jessica Young; Mateusz Opyrchal; Li Yan; Santosh Patnaik; Eigo Otsuji; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2019-04-08       Impact factor: 5.344

2.  ASO Author Reflections: Transitioning From Morphology to Transcriptomics in Capturing Tumor Biology.

Authors:  Hideo Takahashi; Masanori Oshi; Mariko Asaoka; Takashi Ishikawa; Itaru Endo; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2020-05-29       Impact factor: 5.344

3.  HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures.

Authors:  Daniel L Faden; Adam Langenbucher; Krystle Kuhs; James S Lewis; Lisa Mirabello; Meredith Yeager; Joseph F Boland; Sara Bass; Mia Steinberg; Michael Cullen; Michael S Lawrence; Robert L Ferris
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

4.  Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer.

Authors:  Tstutomu Kawaguchi; Li Yan; Qianya Qi; Xuan Peng; Stephen B Edge; Jessica Young; Song Yao; Song Liu; Eigo Otsuji; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2018-10-11       Impact factor: 5.344

5.  Molecular Biological Features of Nottingham Histological Grade 3 Breast Cancers.

Authors:  Hideo Takahashi; Masanori Oshi; Mariko Asaoka; Li Yan; Itaru Endo; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2020-05-20       Impact factor: 5.344

6.  High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.

Authors:  Takashi Takeshita; Mariko Asaoka; Eriko Katsuta; Sara J Photiadis; Sumana Narayanan; Li Yan; Kazuaki Takabe
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

7.  KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Eriko Katsuta; Li Yan; Vikas Satyananda; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

8.  ASO Author Reflections: "From Computer to Bedside": A New Translational Approach to Immunogenomics.

Authors:  Tsutomu Kawaguchi; Sumana Narayanan; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2018-10-26       Impact factor: 5.344

9.  Low expression of miR-195 is associated with cell proliferation, glycolysis and poor survival in estrogen receptor (ER)-positive but not in triple negative breast cancer.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Ankit Patel; Eriko Katsuta; Li Yan; Fernando A Angarita; Subhamoy Dasgupta; Masayuki Nagahashi; Nobuhisa Matsuhashi; Manabu Futamura; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

Review 10.  Current status and limitations of immunotherapy for breast cancer.

Authors:  Yoshihisa Tokumaru; Daniel Joyce; Kazuaki Takabe
Journal:  Surgery       Date:  2019-10-14       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.